Gilead Sciences and Achillion Pharmaceuticals have discontinued the development of GS 9132, also known as ACH-806, for the treatment of hepatitis C viral (HCV) infection. Preliminary data from the Phase Ib/II trial indicated that the compound demonstrated antiviral activity, validating the novel anti-HCV mechanism that involves inhibition of a viral protein called NS4A. However, based on small elevations of serum creatinine (a marker of kidney function), the two companies have elected to shift t...